



## RESEARCH ARTICLE OPEN ACCESS

# Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA-EPIFLUEHA Report

Jon Salmanton-García<sup>1,2,3</sup> | Francesco Marchesi<sup>4</sup> | Milan Navrátil<sup>5,6</sup> | Klára Piukovics<sup>7</sup> | Maria Iliaria del Principe<sup>8</sup> | Marianna Criscuolo<sup>9</sup> | Yavuz M. Bilgin<sup>10</sup> | Nicola S. Fracchiolla<sup>11</sup> | Antonio Vena<sup>12,13</sup> | Alessandra Romano<sup>14</sup> | Iker Falces-Romero<sup>15,16</sup> | Nicola Sgherza<sup>17</sup> | Inmaculada Heras-Fernando<sup>18</sup> | Monika M. Biernat<sup>19</sup> | Verena Petzer<sup>20</sup> | Pavel Žák<sup>21</sup> | Barbora Weinbergerová<sup>22</sup> | Michail Samarkos<sup>23</sup> | Nurettin Erben<sup>24</sup> | Jens van Praet<sup>25</sup> | Alberto López-García<sup>26</sup> | Jorge Labrador<sup>27</sup> | Tobias Lahmer<sup>28</sup> | Luboš Drgoňa<sup>29</sup> | Maria Merelli<sup>30</sup> | Annarosa Cuccaro<sup>31,32</sup> | Sonia Martín-Pérez<sup>33</sup> | Julio Dávila-Valls<sup>33</sup> | Francesca Farina<sup>34</sup> | Chiara Cattaneo<sup>35</sup> | László Imre Pinczés<sup>36</sup> | Ferenc Magyari<sup>36</sup> | Ildefonso Espigado<sup>37</sup> | Caterina Buquicchio<sup>38</sup> | Donald C. Vinh<sup>39</sup> | Igor Stoma<sup>40</sup> | Martin Čerňan<sup>41</sup> | Lucia Prezioso<sup>42</sup> | Mario Virgilio Papa<sup>43</sup> | Gaëtan Plantevefe<sup>44</sup> | Reham Abdelaziz Khedr<sup>45,46</sup> | Josip Batinić<sup>47,48,49</sup> | Gabriele Magliano<sup>50</sup> | Simge Erdem<sup>51</sup> | Sofya Khostelidi<sup>52</sup> | Natasha Čolović<sup>53</sup> | Davide Nappi<sup>54</sup> | Patricia García-Ramírez<sup>55</sup> | Jakub Góra<sup>56</sup> | Marta Callejas-Charavia<sup>55</sup> | Jędrzej Tłusty<sup>56</sup> | Martijn Bakker<sup>57</sup> | Elwira Wojtyniak<sup>58</sup> | Darko Antić<sup>53</sup> | Agnieszka Magdziak<sup>58</sup> | Michelina Dargenio<sup>59</sup> | Larisa Idrizović<sup>1,2</sup> | Nikola Pantić<sup>53</sup> | Zlate Stojanoski<sup>60</sup> | Noha Eisa<sup>61,62</sup> | Vladimir Otašević<sup>53</sup> | Monia Marchetti<sup>63</sup> | Erica Mackenzie<sup>64</sup> | Carolina Garcia-Vidal<sup>65</sup> | Avinash Aujayeb<sup>66</sup> | Ahlam Almasari<sup>62</sup> | Carolina Miranda-Castillo<sup>67</sup> | Eleni Gavriilaki<sup>68</sup> | Nicola Coppola<sup>69</sup> | Alessandro Busca<sup>70</sup> | Tatjana Adžić-Vukičević<sup>53</sup> | Martin Schönlein<sup>71</sup> | Ditte Stampe Hersby<sup>72</sup> | Stefanie K. Gräfe<sup>73</sup> | Andreas Glenthøj<sup>72</sup> | Tommaso Francesco Aiello<sup>65</sup> | Milche Cvetanoski<sup>60</sup> | Mirjana Mitrović<sup>53</sup> | Claudio Cerchione<sup>54</sup> | Romane Prin<sup>74</sup> | Gina Varricchio<sup>43</sup> | Elena Arellano<sup>37</sup> | Raúl Córdoba<sup>26</sup> | Jiří Mayer<sup>22</sup> | Benjamín Víšek<sup>21</sup> | Dominik Wolf<sup>20</sup> | Amalia N. Anastasopoulou<sup>23</sup> | Mario Delia<sup>17</sup> | Pellegrino Musto<sup>17</sup> | Dario Leotta<sup>14</sup> | Martina Bavastro<sup>12,13</sup> | Alessandro Limongelli<sup>12,13</sup> | Mariarita Sciume<sup>11</sup> | Lukas van den Ven<sup>1,2</sup> | Luana Fianchi<sup>9</sup> | Sara Caterina Brunetti<sup>9</sup> | Joanna Drozd-Sokołowska<sup>56</sup> | Anna Dąbrowska-Iwanicka<sup>75</sup> | Oliver A. Cornely<sup>1,2,3,76</sup> | Livio Pagano<sup>9,77</sup>

**Correspondence:** Jon Salmanton-García ([jon.salmanton-garcia@uk-koeln.de](mailto:jon.salmanton-garcia@uk-koeln.de)) | Livio Pagano ([livio.pagano@unicatt.it](mailto:livio.pagano@unicatt.it))

**Received:** 16 October 2024 | **Revised:** 18 November 2024 | **Accepted:** 3 December 2024

**Funding:** The authors received no specific funding for this work.

**Keywords:** antiviral therapy | community-acquired respiratory viral infection | hematological malignancy | secondary infection | vaccine coverage

## ABSTRACT

Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS-CoV-2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the

Jon Salmanton-García and Francesco Marchesi shared junior authorship.

Oliver A. Cornely and Livio Pagano shared senior authorship.

For affiliations refer to page 14.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Author(s). *American Journal of Hematology* published by Wiley Periodicals LLC.

severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.

## 1 | Introduction

Community-acquired respiratory viral infections (CARV) are a significant concern for patients with hematological malignancy (HM), whether they have undergone hematopoietic stem cell transplantation (HSCT) or not [1–3]. CARV can severely compromise the effectiveness of anticancer treatments, making them one of the most challenging complications in HM patients [2, 4]. In recent years, there has been a growing understanding of the importance and the management of CARV in HM. A rising interest is reflected in the increasing body of scientific literature exploring the role and impact of CARV, including consensus guidelines [5–7]. However, large-scale data from cooperative registries, which are crucial for developing real-world, evidence-based strategies, remain scarce. Such data could be invaluable to the hematology community, providing critical insights into the epidemiology, risk factors, and clinical outcomes of CARV in HM patients. With this knowledge, clinicians could more effectively mitigate the adverse effects of these infections on the overall treatment process.

The EPICOVIDEHA registry [8], established in 2021, has been instrumental in addressing this gap by collecting extensive data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in HM patients. The insights from EPICOVIDEHA registry have led to numerous scientific publications that have been vital in guiding clinicians throughout the coronavirus disease 2019 (COVID-19) pandemic, helping to develop preventive strategies to protect HM patients [9–29]. Building on the success of the SARS-CoV-2-dedicated data collection, the EPICOVIDEHA registry expanded its scope in 2023 to include other CARV and was renamed as EPICOVIDEHA-EPIFLUEHA [30]. This expansion aimed to provide a more comprehensive understanding of the epidemiology, risk factors, and clinical outcomes associated with CARV in HM patients.

In this manuscript, we present and analyze CARV cases in HM patients registered during the autumn–winter seasons of 2023–2024. Our goal is to contribute valuable data that can guide future strategies in the ongoing effort to improve care for HM patients facing the threat of respiratory viral infections.

## 2 | Methods

### 2.1 | Patients

A total of 61 institutions from 24 countries (Figure S1) contributed data on CARV cases diagnosed between September 1, 2023, and March 31, 2024, in HM patients to the EPICOVIDEHA-EPIFLUEHA registry [8, 30], accessible at [www.clinicalstudies.net](http://www.clinicalstudies.net) (EFS, TIVIAN, Cologne, Germany). EPICOVIDEHA-EPIFLUEHA, identified by National Clinical Trials Identifier

NCT04733729, is an international, web-based registry focused on HM adult patients who contract CARV. It was established by the European Hematology Association Specialized Working Group (EHA-SWG) Infections in Hematology.

Patients were eligible if they had an active HM within the last 5 years immediately before the CARV diagnosis, were 18 years or older, had a laboratory-confirmed CARV, and received their diagnosis between September 1, 2023, and March 31, 2024. The period from September 2023 to March 2024 was chosen as it aligns with the peak season for CARV infections in the Northern hemisphere [31], enabling a representative analysis in terms of comparability and impact on healthcare systems. Excluded were patients with solid tumors, nonmalignant hematological disorders, age < 18 years, those off-therapy or cured for more than 5 years before their respiratory viral infection, or those diagnosed solely via imaging. No restrictions were imposed concerning the type of pathogenic virus.

For each patient, data collected included baseline conditions prior to the CARV, such as age, biological sex, and HM status at diagnosis. Information on HM management (status and type of last treatment before infection), CARV diagnosis and symptomatology, prophylaxis and treatments (including vaccines against influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 administered within the year preceding the onset of infection), stay during infection, and outcomes (mortality and last follow-up date) were recorded. Patients who received an influenza, RSV, or SARS-CoV-2 vaccination more than 1 year prior to their CARV infection diagnosis were classified as “non-vaccinated” for the purposes of this analysis. The status of HM at infection onset was classified as active (onset, refractory, and stable disease) or controlled (complete response). The severity of respiratory viral infection episodes was categorized as asymptomatic, mild, severe, or critical, as in previous EPICOVIDEHA-EPIFLUEHA publications [22, 23, 25]. To ensure data accuracy and completeness, a validation process was conducted by experts in hematology and infectious diseases. Contributors were contacted to resolve any pending queries, which helped maintain the integrity and reliability of the registry data. Missing data for variables included in regression analyses led to exclusion from the analysis.

### 2.2 | Objectives

The primary objective was to examine the epidemiology and outcomes of HM patients affected by respiratory viruses during the specified period. Secondary objectives included determining the relative frequency of disease severity, intensive care unit (ICU) admissions, overall case-fatality rate, the impact of cancer treatment phases on outcomes, the effect of vaccine doses on outcomes, and the impact of treatment strategies for respiratory viral infections.

## 2.3 | Statistical Analysis

As an exploratory study, no a priori sample size calculation was performed. Data were summarized using frequencies and percentages for categorical variables and median, interquartile range (IQR), and absolute range for continuous variables. A univariable Cox regression model analyzed factors influencing mortality in HM patients with respiratory viral infections. Clinically relevant variables were considered for multivariable analysis, which was conducted using the Wald backward method. Variables were included in the multivariable Cox regression model based on a statistical significance threshold ( $p \leq 0.05$ ). Mortality per viral pathogen was analyzed using Kaplan–Meier survival plots, with survival probabilities compared via log-rank test. The Cox proportional hazards model was used to analyze variables impacting mortality, including biological sex, age, vaccination status at infection onset, infecting viral pathogen, comorbidities, neutrophil and lymphocyte counts, baseline HM, HM status at infection diagnosis, last chemotherapy strategy, symptoms at infection onset, treatment strategies, hospitalization during the infection episode, and secondary infections (bacterial, fungal, or other viral). Hazard ratios (HR) and 95% confidence intervals (CI) were reported to quantify associations, with  $p \leq 0.05$  considered statistically significant. Statistical analyses were performed using SPSS version 25.0 (SPSS, IBM Corp, Chicago, IL, USA).

## 2.4 | Ethics Statement

The registry received ethical approval from the local ethics committee of the Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Università Cattolica del Sacro Cuore in Rome, Italy (Study ID: 3226), as well as from the respective ethics committees of participating institutions when required. The registry was further amended at the end of 2023 and named EPICOVIDEHA-EPIFLUEHA (Study ID: 113/23 del 03/01/2023). The anonymized data that do not contain any personally identifiable information from any sources implies that the informed consent is not applicable.

## 2.5 | Role of the Funding Source

This research did not receive any funding. J.S.G., F.M., L.P., and O.A.C. had access to and verified all raw datasets and decided to submit the article.

## 3 | Results

During the boreal Autumn–Winter of 2023–2024, EPICOVIDEHA-EPIFLUEHA registered 1312 patients from 24 countries (Figures S1–S3). Among them, 48.7% ( $n = 639/1312$ ) were diagnosed with SARS-CoV-2, 19.1% ( $n = 250/1312$ ) with influenza, 12.3% ( $n = 135/1312$ ) with RSV, and 9.8% ( $n = 128/1312$ ) with rhinovirus. There were also cases of infections from parainfluenza (2.4%,  $n = 31/1312$ ), metapneumovirus (2.1%,  $n = 28/1312$ ), non-SARS-CoV-2 coronaviruses (1.5%,  $n = 20/1312$ ), and enterovirus/rhinovirus (1.4%,  $n = 18/1312$ ).

Additionally, 4.5% ( $n = 59/1312$ ) had multiple viral infections, mostly involving influenza (44.1%,  $n = 26/59$ ) or SARS-CoV-2 (57.6%,  $n = 34/59$ ). Of these, 93.2% ( $n = 55/59$ ) had two viruses, whereas 6.8% ( $n = 4/59$ ) had three. The most common coinfections were influenza plus SARS-CoV-2 (20.3%,  $n = 12/59$ ) and RSV plus SARS-CoV-2 (18.6%,  $n = 11/59$ ) (Table 1).

Among the patients documented, 54.8% ( $n = 719/1312$ ) were male. The highest male-to-female ratios were seen in cases of influenza (58.8%,  $n = 147/250$ ) and enterovirus/rhinovirus infections (61.1%,  $n = 11/18$ ). The median age of the patients was 65 years (IQR 54–73, range of 18–96). The youngest patients were those with adenovirus or bocavirus infections, with a median age of 44 years (IQR 36–59, range 32–70), while the oldest were those with SARS-CoV-2 infections, with a median age of 66 years (IQR 57–73, range 19–95). Regarding viral infections with an available vaccination schedule, limited to influenza H1N1 and SARS-CoV-2, only 5.3% (70 out of 1312) of the patients had been vaccinated against the respective virus, with the vaccination occurring a median of 79 days before the diagnosis of the infection (IQR 54–125, range 0–346). About 28.9% ( $n = 379/1312$ ) of patients had two or more comorbidities. The most common underlying conditions were chronic heart disease (42.5%,  $n = 558/1312$ ), chronic lung disease (13.6%,  $n = 179/1312$ ), diabetes mellitus (13.6%,  $n = 178/1312$ ), and a history of smoking (12.4%,  $n = 79/1312$ ). Chronic heart disease was the most prevalent underlying condition regardless of the viral infection, although other major conditions did vary depending on the virus. Neutropenia (fewer than 500 neutrophils/mm<sup>3</sup>) was observed in 9.8% ( $n = 128/1312$ ) of patients, and lymphopenia (200 or fewer lymphocytes/mm<sup>3</sup>) was seen in 10.9% ( $n = 143/1312$ ) (Tables 1 and S1, and Figure S4).

Lymphomas were the most common underlying HM, affecting 30.6% ( $n = 401/1312$ ) of the patients, with 27.6% ( $n = 362/1312$ ) having non-Hodgkin lymphoma. Other significant malignancies included plasma cell malignancies (22.3%,  $n = 293/1312$ ) and acute myeloid leukemia (19.7%,  $n = 259/1312$ ). Among influenza patients, plasma cell malignancies were the most common (28.0%,  $n = 70/250$ ), whereas for metapneumovirus infections, lymphomas and plasma cell malignancies were equally prevalent (28.6%,  $n = 8/28$  each). At the time of diagnosis of the viral infection, 49.6% ( $n = 651/1312$ ) of the patients had a controlled underlying malignancy, whereas 50.4% ( $n = 661/1312$ ) had an active malignancy. Two thirds of the patients (63.7%,  $n = 836/1312$ ) had undergone drug-based chemotherapy in the 3 months prior to their infection diagnosis, and 8.3% ( $n = 109/1312$ ) had received either chimeric antigen receptor T-cell (CAR-T) therapy or an HSCT in the prior 6 months. Most viral infections were diagnosed between November 2023 (16.5%,  $n = 216/1312$ ) and January 2024 (21.3%,  $n = 280/1312$ ), with a peak in December 2023 (24.5%,  $n = 321/1312$ ). SARS-CoV-2 was the most prevalent pathogen from September to December 2023 (60.1%–71.5% of all infections in the period), while influenza was more common from January to March 2024 (20.5%–40.4% of all infections in the period). RSV infections were high in February 2024 (24.6%,  $n = 43/175$ ), and metapneumovirus infections peaked in March 2024 (18.1%,  $n = 15/83$ ) (Tables 1 and S1 and Figure 1 and S3–S5).

Most patients experienced either asymptomatic (9.6%,  $n = 126/1312$ ) or mild infections (66.5%,  $n = 872/1312$ ). Critical

**TABLE 1** | Profile of EPICOVIDEHA-EPIFLUEHA patients during the Winter season: September 2023–March 2024.

	Overall		SARS-CoV-2		Influenza		RSV	
	<b>n = 1312, 100.0%</b>		<b>n = 639, 48.7%</b>		<b>n = 250, 19.1%</b>		<b>n = 135, 10.3%</b>	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Sex								
Female	593	45.2	304	47.6	103	41.2	59	43.7
Male	719	54.8	335	52.4	147	58.8	76	56.3
Age	65 (54–73) [18–96]		66 (57–73) [19–95]		64 (55–73) [18–93]		63 (53–71) [18–87]	
Vaccination at infection onset								
Not vaccinated	1242	94.7	617	96.6	208	83.2	134	99.3
Influenza	44	3.4	0	0.0	42	16.8	0	0.0
RSV	3	0.2	0	0.0	0	0.0	1	0.7
SARS-CoV-2	23	1.8	22	3.4	0	0.0	0	0.0
<i>Days from last vaccination to infection</i>	79 (54–125) [0–346]		180 (31–319) [0–346]		73 (54–89) [0–344]		80 (80–80) [80–80]	
Comorbidities								
0–1	933	71.1	439	68.7	175	70.0	100	74.1
2+	379	28.9	200	31.3	75	30.0	35	25.9
<i>Chronic cardiopathy</i>	558	42.5	304	47.6	123	49.2	49	36.3
<i>Chronic pulmonary disease</i>	179	13.6	79	12.4	39	15.6	13	9.6
<i>Diabetes mellitus</i>	178	13.6	95	14.9	31	12.4	17	12.6
<i>Liver disease</i>	44	3.4	14	2.2	12	4.8	6	4.4
<i>Obesity (BMI &gt; 30)</i>	72	5.5	36	5.6	17	6.8	10	7.4
<i>Renal impairment</i>	89	6.8	52	8.1	14	5.6	6	4.4
<i>Smoking history</i>	151	11.5	79	12.4	34	13.6	15	11.1
Neutrophils								
< 500	128	9.8	50	7.8	23	9.2	23	17.0
500–999	101	7.7	40	6.3	25	10.0	15	11.1
≥ 1000	921	70.2	454	71.0	181	72.4	84	62.2

(Continues)

TABLE 1 | (Continued)

	Overall		SARS-CoV-2		Influenza		RSV	
	<b>n = 1312, 100.0%</b>		<b>n = 639, 48.7%</b>		<b>n = 250, 19.1%</b>		<b>n = 135, 10.3%</b>	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Lymphocytes								
≤200	143	10.9	45	7.0	37	14.8	23	17.0
201–499	194	14.8	87	13.6	46	18.4	27	20.0
≥500	800	61.0	405	63.4	146	58.4	73	54.1
Baseline hematological malignancy								
Lymphoma	401	30.6	214	33.5	59	23.6	41	30.4
<i>Hodgkin lymphoma</i>	39	3.0	14	2.2	6	2.4	5	3.7
<i>Non-Hodgkin lymphoma</i>	362	27.6	200	31.3	53	21.2	36	26.7
Plasma cell malignancies	293	22.3	140	21.9	70	28.0	31	23.0
<i>Amyloid light-chain amyloidosis</i>	7	0.5	5	0.8	0	0.0	0	0.0
<i>Multiple myeloma</i>	286	21.8	135	21.1	70	28.0	31	23.0
Acute myeloid leukemia	259	19.7	107	16.7	57	22.8	31	23.0
Acute lymphoblastic leukemia	84	6.4	32	5.0	11	4.4	14	10.4
Chronic lymphocytic leukemia	121	9.2	78	12.2	17	6.8	10	7.4
<i>Chronic lymphocytic leukemia</i>	113	8.6	75	11.7	15	6.0	9	6.7
<i>Hairy cell leukemia</i>	8	0.6	3	0.5	2	0.8	1	0.7
Myelodysplastic syndrome	82	6.3	36	5.6	22	8.8	5	3.7
Chronic myeloid malignancies	59	4.5	26	4.1	12	4.8	2	1.5
<i>Chronic myeloid leukemia</i>	24	1.8	11	1.7	3	1.2	0	0.0
<i>Myelofibrosis</i>	20	1.5	6	0.9	7	2.8	2	1.5
<i>Essential thrombocythemia</i>	7	0.5	5	0.8	0	0.0	0	0.0
<i>Polycythaemia vera</i>	6	0.5	2	0.3	2	0.8	0	0.0
<i>Systemic mastocytosis</i>	2	0.2	2	0.3	0	0.0	0	0.0
Aplastic anemia	13	1.0	6	0.9	2	0.8	1	0.7

(Continues)

TABLE 1 | (Continued)

	Overall		SARS-CoV-2		Influenza		RSV	
	<i>n</i> = 1312, 100.0%		<i>n</i> = 639, 48.7%		<i>n</i> = 250, 19.1%		<i>n</i> = 135, 10.3%	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
Status of baseline hematological malignancy								
Controlled malignancy	651	49.6	311	48.7	119	47.6	67	49.6
Active malignancy	661	50.4	328	51.3	131	52.4	68	50.4
Last chemotherapy strategy before infection diagnosis								
Conventional chemotherapy	238	18.1	101	15.8	48	19.2	32	23.7
< 3 months	197	15.0	84	13.1	42	16.8	26	19.3
> 3 months	41	3.1	17	2.7	6	2.4	6	4.4
Demethylating agents	86	6.6	36	5.6	29	11.6	8	5.9
< 3 months	78	5.9	32	5.0	27	10.8	8	5.9
> 3 months	8	0.6	4	0.6	2	0.8	0	0.0
Immuno-chemotherapy	468	35.7	272	42.6	81	32.4	39	28.9
< 3 months	389	29.6	231	36.2	67	26.8	31	23.0
> 3 months	79	6.0	41	6.4	14	5.6	8	5.9
Targeted therapy	188	14.3	101	15.8	42	16.8	19	14.1
< 3 months	172	13.1	96	15.0	35	14.0	18	13.3
> 3 months	16	1.2	5	0.8	7	2.8	1	0.7
alloHSCT	129	9.8	36	5.6	17	6.8	17	12.6
< 6 months	55	4.2	14	2.2	7	2.8	8	5.9
> 6 months	74	5.6	22	3.4	10	4.0	9	6.7
autoHSCT	47	3.6	16	2.5	8	3.2	6	4.4
< 6 months	43	3.3	14	2.2	7	2.8	6	4.4
> 6 months	4	0.3	2	0.3	1	0.4	0	0.0
CAR-T	15	1.1	5	0.8	2	0.8	2	1.5
< 6 months	11	0.8	3	0.5	1	0.4	2	1.5

(Continues)

TABLE 1 | (Continued)


	Overall		SARS-CoV-2		Influenza		RSV	
	<i>n</i> = 1312, 100.0%		<i>n</i> = 639, 48.7%		<i>n</i> = 250, 19.1%		<i>n</i> = 135, 10.3%	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
> 6 months	4	0.3	2	0.3	1	0.4	0	0.0
No treatment	119	9.1	65	10.2	17	6.8	9	6.7
Supportive measures	23	1.8	7	1.1	7	2.8	3	2.2
Viral diagnosis month								
September 2023	86	6.6	56	8.8	0	0.0	0	0.0
October 2023	151	11.5	108	16.9	4	1.6	6	4.4
November 2023	216	16.5	151	23.6	7	2.8	13	9.6
December 2023	321	24.5	193	30.2	49	19.6	35	25.9
January 2024	280	21.3	94	14.7	113	45.2	27	20.0
February 2024	175	13.3	27	4.2	60	24.0	43	31.9
March 2024	83	6.3	10	1.6	17	6.8	11	8.1
Symptoms at viral infection onset								
No symptoms	512	39.0	169	26.4	43	17.2	90	66.7
Extrapulmonary symptoms	704	53.7	449	70.3	196	78.4	20	14.8
Pulmonary symptoms	21	1.6	0	0.0	0	0.0	9	6.7
Viral infection severity								
Asymptomatic	126	9.6	99	15.5	5	2.0	8	5.9
Mild	872	66.5	427	66.8	163	65.2	81	60.0
Severe	211	16.1	73	11.4	52	20.8	37	27.4
Critical	103	7.9	40	6.3	30	12.0	9	6.7
Viral infection treatment								
No treatment	512	39.0	169	26.4	43	17.2	90	66.7
Antivirals ± corticosteroids	704	53.7	449	70.3	196	78.4	20	14.8
Immunoglobulins	21	1.6	0	0.0	0	0.0	9	6.7

(Continues)

TABLE 1 | (Continued)

	Overall		SARS-CoV-2		Influenza		RSV	
	<b>n = 1312, 100.0%</b>		<b>n = 639, 48.7%</b>		<b>n = 250, 19.1%</b>		<b>n = 135, 10.3%</b>	
	n	%	n	%	n	%	n	%
Corticosteroids	65	5.0	15	2.3	9	3.6	14	10.4
Immunoglobulins in combination	10	0.8	6	0.9	2	0.8	2	1.5
Secondary infections	242	18.4	100	15.6	36	14.4	33	24.4
Bacterial	177	13.5	74	11.6	23	9.2	27	20.0
Fungal	53	4.0	20	3.1	12	4.8	8	5.9
Other viral	53	4.0	21	3.3	4	1.6	5	3.7
Patient stay during viral infection								
Home	548	41.8	324	50.7	83	33.2	38	28.1
Hospital	739	56.3	306	47.9	162	64.8	94	69.6
Hospital, non-ICU	636	48.5	266	41.6	132	52.8	85	63.0
Hospital, ICU	103	7.9	40	6.3	30	12.0	9	6.7
Invasive MV	43	41.7	15	37.5	12	40.0	6	66.7
Noninvasive MV	34	33.0	9	22.5	13	43.3	3	33.3
Not reported	25	24.3	9	22.5	5	16.7	3	33.3
Mortality D30	77	5.9	32	5.0	22	8.8	8	5.9
Reason for mortality								
Hematological malignancy	50	3.8	23	3.6	12	4.8	6	4.4
Viral infection	49	3.7	23	3.6	18	7.2	2	1.5
Other reasons	36	2.7	12	1.9	9	3.6	5	3.7

Abbreviations: alloHSCT, allogeneic hematopoietic stem cell transplantation; aut of HSCT, autologous hematopoietic stem cell transplantation; BMI, body mass index; CAR-T, chimeric antigen receptor T-cell therapy; Dd30, Day 30; ICU, intensive care unit; MV, mechanical ventilation; n, number; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.



**FIGURE 1** | Community-acquired respiratory viral infection distribution per baseline hematological malignancy in EPICOVIDEHA-EPIFLUEHA participants with hematological patients diagnosed with respiratory viral infections (September 2023–March 2024).

infections were reported in 7.9% ( $n = 103/1312$ ) of cases, with higher rates seen in parainfluenza (16.1%,  $n = 5/31$ ), metapneumovirus (14.3%,  $n = 4/28$ ), and influenza infections (12.0%,  $n = 30/250$ ). A total of 56.3% ( $n = 739/1312$ ) of patients required hospital admission, with the highest rate among those with RSV infections (69.6%,  $n = 94/135$ ). A total of 103/1312 patients (7.9%) were admitted to the ICU, with 43/103 (41.7%) requiring mechanical ventilation. The highest ICU admission rates were seen in patients with parainfluenza (16.1%,  $n = 5/31$ ) and metapneumovirus (14.3%,  $n = 4/22$ ) (Table S1). No treatment was given to 39% ( $n = 512/1312$ ) of patients. Among those who did receive treatment, the most common were antivirals, with or without corticosteroids (53.7%,  $n = 704/1312$ ), especially for influenza (78.4%,  $n = 196/250$ ) and SARS-CoV-2 infections (70.3%,  $n = 449/639$ ). Secondary infections occurred in 18.4% ( $n = 242/1312$ ) of patients, with bacterial infections being the most common (13.5%,  $n = 177/1312$ ). The highest rates of secondary bacterial infections were observed in enterovirus/rhinovirus co-infections (38.9%,  $n = 7/18$ ), rhinovirus infections (21.1%,  $n = 27/128$ ), and RSV infections (20.0%,  $n = 27/135$ ). Fungal and other viral secondary infections were less common overall (4%,  $n = 53/1312$  each), though they were relatively more frequent in parainfluenza (9.7%,  $n = 3/31$ ) and metapneumovirus infections (10.7%,  $n = 3/28$ ) (Tables 1 and S1).

The overall 30-day mortality rate was 5.9% (77/1312). Parainfluenza infections had the highest all-cause mortality rate at 19.4% (6/31), surpassing other common CARV such as influenza (8.8%, 22/250) and SARS-CoV-2 (5.0%, 32/639). The highest CARV-attributable mortality rates were observed in influenza at 81.8% (18/22) and SARS-CoV-2 at 63.6% (49/77). Additionally, the progression of the underlying malignancy contributed to 64.9% (50/77) of the total deaths (Tables 1 and S1 and Figure S6).

Moreover, a pool of patients with the most prevalent pathogenic viruses was established, including cases of mono-infection from SARS-CoV-2, influenza, RSV, rhinovirus, parainfluenza, and metapneumovirus. The following factors were associated with increased mortality in the multivariable analysis (Table 2): parainfluenza infection ( $p = 0.040$ , adjusted HR [aHR] 3.326, 95% CI 1.058–10.453), baseline smoking history ( $p = 0.028$ , aHR 3.867, 95% CI 1.156–12.930), secondary bacterial infection ( $p < 0.001$ , aHR 4.023, 95% CI 2.110–7.673), and hospital admission, regardless whether to a normal ward ( $p = 0.018$ , aHR 11.683, 95% CI 1.535–88.929) or to an ICU ( $p < 0.001$ , aHR 49.946, 95% CI 6.462–386.020). Conversely, reduced mortality was associated with the absence of lymphopenia (201–499 lymphocytes/mm<sup>3</sup>,  $p < 0.001$ , aHR 0.173, 95% CI 0.063–0.481; 500–999 lymphocytes/mm<sup>3</sup>,  $p = 0.002$ , aHR 0.381, 95% CI 0.206–0.704) (Table 2). Furthermore, Kaplan–Meier survival plots indicated significantly higher survival probabilities in SARS-CoV-2 patients compared with those with influenza ( $p = 0.006$ ) or parainfluenza ( $p < 0.001$ ), also a higher survival probability in rhinovirus patients compared with those with influenza ( $p = 0.009$ ) and parainfluenza ( $p < 0.001$ ), and in RSV patients compared with those with parainfluenza ( $p = 0.048$ ) (Figure 2).

Sensitivity analyses were conducted to identify factors associated with increased mortality in patients with SARS-CoV-2, influenza, and RSV infections, respectively. For SARS-CoV-2 infections, Cox multivariable regression analysis identified myelodysplastic syndrome ( $p = 0.005$ , aHR 6.102, 95% CI 1.705–21.842), active malignancy ( $p = 0.036$ , aHR 3.884, 95% CI 1.093–13.519), fungal secondary infection ( $p = 0.037$ , aHR 3.761, 95% CI 1.084–13.051), and hospital admission, either in a non-ICU ( $p = 0.014$ , aHR 13.319, 95% CI 1.704–104.137) or ICU ward ( $p = 0.001$ , aHR 39.351, 95% CI 4.384–353.185), as factors

**TABLE 2** | Factors associated with increased mortality in a pool of SARS-CoV-2, influenza, respiratory syncytial virus, rhinovirus, parainfluenza, and metapneumovirus.

	Univariable analysis				Multivariable analysis			
	p	HR	95% CI		p	HR	95% CI	
			Lower	Upper			Lower	Upper
Sex								
Female	—	—	—	—	—	—	—	—
Male	0.110	1.478	0.915	2.386	—	—	—	—
Age	0.053	1.017	1.000	1.034	0.196	1.013	0.993	1.033
Vaccination at infection onset								
Not vaccinated	—	—	—	—	—	—	—	—
Influenza	0.258	1.790	0.653	4.909	—	—	—	—
RSV	0.971	—	—	—	—	—	—	—
SARS-CoV-2	0.712	0.690	0.096	4.968	—	—	—	—
Viruses								
SARS-CoV-2	—	—	—	—	—	—	—	—
Influenza	0.006*	2.138	1.241	3.681	0.062	1.985	0.966	4.077
RSV	0.312	1.492	0.687	3.240	0.595	0.770	0.294	2.019
Rhinovirus	0.232	0.486	0.149	1.587	0.162	0.343	0.077	1.538
Parainfluenza	0.001*	4.234	1.770	10.130	0.040*	3.326	1.058	10.453
Metapneumovirus	0.320	2.064	0.494	8.621	0.507	1.674	0.365	7.666
Comorbidities								
0–1	—	—	—	—	—	—	—	—
2+	0.228	1.343	0.832	2.168	—	—	—	—
<i>Chronic cardiopathy</i>	0.303	0.786	0.497	1.243	—	—	—	—
<i>Chronic pulmonary disease</i>	0.599	0.842	0.443	1.598	—	—	—	—
<i>Diabetes mellitus</i>	0.071	0.593	0.336	1.046	—	—	—	—
<i>Liver disease</i>	0.014*	0.352	0.152	0.810	0.073	0.372	0.126	1.097
<i>Obesity (BMI &gt; 30)</i>	0.992	1.005	0.367	2.754	—	—	—	—
<i>Renal impairment</i>	0.938	1.037	0.418	2.570	—	—	—	—
<i>Smoking history</i>	0.046*	3.247	1.022	10.311	0.028*	3.867	1.156	12.930
Neutrophils								
< 500	—	—	—	—	—	—	—	—
500–999	0.277	0.552	0.189	1.614	0.878	1.096	0.340	3.532
≥ 1000	0.089	0.551	0.278	1.094	0.249	1.671	0.698	4.000
Lymphocytes								
≤ 200	—	—	—	—	—	—	—	—
201–499	< 0.001*	0.179	0.072	0.445	< 0.001*	0.173	0.063	0.481
≥ 500	< 0.001*	0.213	0.122	0.372	0.002*	0.381	0.206	0.704

(Continues)

TABLE 2 | (Continued)

	Univariable analysis				Multivariable analysis			
	p	HR	95% CI		p	HR	95% CI	
			Lower	Upper			Lower	Upper
Baseline hematological malignancy								
Lymphoma	—	—	—	—	—	—	—	—
Plasma cell malignancies	0.136	0.583	0.287	1.185	—	—	—	—
Acute myeloid leukemia	0.182	0.607	0.291	1.263	—	—	—	—
Chronic lymphocytic leukemia	0.917	1.043	0.471	2.313	—	—	—	—
Acute lymphoblastic leukemia	0.862	1.089	0.417	2.844	—	—	—	—
Myelodysplastic syndrome	0.504	1.331	0.576	3.077	—	—	—	—
Chronic myeloid malignancies	0.105	2.001	0.865	4.628	—	—	—	—
Aplastic anemia	0.970	—	—	—	—	—	—	—
Status hematological malignancy at infection onset								
Controlled malignancy	—	—	—	—	—	—	—	—
Active malignancy	<0.001*	3.940	2.233	6.951	0.068	1.850	0.956	3.579
Last chemotherapy strategy before infection								
Conventional chemotherapy	—	—	—	—	—	—	—	—
Demethylating agents	0.574	0.753	0.279	2.027	0.479	0.558	0.111	2.799
Immunochemotherapy	0.194	0.669	0.365	1.226	0.259	0.611	0.260	1.436
Targeted therapy	0.431	0.740	0.349	1.566	0.651	0.787	0.278	2.224
alloHSCT	0.033*	0.204	0.047	0.878	0.876	0.869	0.149	5.061
autoHSCT	0.962	—	—	—	0.975	—	—	—
CAR-T	0.966	1.045	0.139	7.828	0.997	—	—	—
No treatment	0.767	1.124	0.519	2.434	0.243	1.852	0.659	5.210
Supportive measures	0.627	0.607	0.081	4.549	0.552	0.492	0.047	5.105
Symptoms at viral infection onset								
No symptoms	—	—	—	—	—	—	—	—
Extrapulmonary symptoms	0.275	0.631	0.276	1.441	0.243	0.551	0.203	1.498
Pulmonary symptoms	0.006*	2.929	1.371	6.260	0.665	1.223	0.492	3.042
Infection treatment								
No treatment	—	—	—	—	—	—	—	—
Antivirals ± corticosteroids	0.282	1.333	0.789	2.251	0.115	1.986	0.846	4.663
Immunoglobulins	0.723	1.437	0.193	10.689	0.360	3.142	0.271	36.402
Corticosteroids	0.008*	3.187	1.355	7.496	0.216	1.955	0.677	5.645
Immunoglobulins in combination	0.031*	4.929	1.155	21.032	0.169	3.457	0.591	20.222
Secondary bacterial infection	<0.001*	4.605	2.881	7.359	<0.001*	4.023	2.110	7.673
Secondary fungal infection	<0.001*	4.406	2.320	8.366	0.331	1.524	0.652	3.565
Secondary viral infection	0.212	1.782	0.719	4.420	—	—	—	—


(Continues)

**TABLE 2** | (Continued)

	Univariable analysis				Multivariable analysis			
	p	HR	95% CI		p	HR	95% CI	
			Lower	Upper			Lower	Upper
Patient stay during infection episode								
Home	—	—	—	—	—	—	—	—
Hospital, non-ICU	<0.001*	21.494	5.206	88.743	0.018*	11.683	1.535	88.929
Hospital, ICU	<0.001*	102.053	24.298	428.622	<0.001*	49.946	6.462	386.020
Not reported	0.971	—	—	—	0.977	—	—	—

Note: \*Statistically significant difference.

Abbreviations: alloHSCT, allogeneic hematopoietic stem cell transplant; autoHSCT, autologous hematopoietic stem cell transplant; BMI, body mass index; CAR-T, chimeric antigen receptor T-cell; CI, confidence interval; HR, hazard ratio; ICU, intensive care unit; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.



**Number of patients at risk**

Pathogen	0	10	20	30
SARS-CoV-2	639	603	546	500
Influenza	250	211	158	124
RSV	135	110	82	68
Rhinovirus	128	119	103	95
Parainfluenza	31	27	26	17
Metapneumovirus	28	21	13	11

**FIGURE 2** | Day 30 survival probability by respiratory viral pathogen.

associated with increased mortality. Conversely, the absence of lymphopenia was a protective factor (201–499 lymphocytes/mm<sup>3</sup>,  $p=0.011$ , aHR 0.177, 95% CI 0.047–0.672; 500–999 lymphocytes/mm<sup>3</sup>,  $p=0.001$ , aHR 0.170, 95% CI 0.059–0.492). In influenza patients, secondary bacterial infection was associated with increased mortality in the multivariable analysis ( $p<0.001$ , aHR 10.837, 95% CI 4.085–28.750), while the

absence of lymphopenia was protective (201–499 lymphocytes/mm<sup>3</sup>,  $p=0.008$ , aHR 0.058, 95% CI 0.007–0.479; 500–999 lymphocytes/mm<sup>3</sup>,  $p=0.006$ , aHR 0.260, 95% CI 0.099–0.684). For RSV infections, multivariable analysis indicated that secondary bacterial ( $p=0.006$ , aHR 9.830, 95% CI 1.902–50.815) and viral ( $p=0.031$ , aHR 6.298, 95% CI 1.182–33.551) infections were associated with an increased risk of mortality (Tables S2–S4).

## 4 | Discussion

Our study highlights the major burden of CARV infections in HM patients, with SARS-CoV-2, influenza, and RSV being the most prevalent. Increased mortality has been seen to be linked to active HM, secondary bacterial infections, and ICU admission, while the absence of lymphopenia offers protection. The findings reveal that the impact of these infections varied by CARV, underscoring the need for tailored management strategies. This stresses the importance of adapting treatment approaches and maintaining vigilant monitoring to address the evolving nature of CARV infections in HM patients.

Pathogen distribution and seasonal peaks align with known CARV circulation trends in the Northern hemisphere [2, 3, 5–7, 32]. From September to December 2023, SARS-CoV-2 was the most prevalent virus in our patients, likely driven by highly transmissible variants [33], potentially insufficient vaccine coverage [34, 35], and increased social activities and gatherings during the holidays [36]. Of note, SARS-CoV-2 infection levels have been described to be less affected by environmental temperature changes [37]. Conversely, influenza increased from January to March 2024, reflecting its typical seasonal rise [38] and reclaiming prominence after recent years where SARS-CoV-2 was the dominant CARV [39, 40]. This shift may be linked to the relaxing of COVID-19-related precautions that had previously kept influenza rates low. RSV and metapneumovirus peaked in February and March 2024, respectively, while rhinovirus remained consistently present but at low levels throughout the study. This multi-pathogen scenario highlights the need for comprehensive preventive measures and increased vigilance, particularly for high-risk groups such as patients with HM.

The study found a limited vaccination rate for influenza, RSV, and SARS-CoV-2—CARV with currently available vaccines—[41] highlighting a major gap in preventive care. This is especially concerning for HM patients, who are at higher risk for severe infection, as compared with the general population. In parallel, the median time between vaccination and infection was 79 days, which could suggest a waning immunity over time. To overcome the situation, strategies like more frequent boosters [42] or passive immunization might be necessary [18]. Besides, understanding the reasons for low vaccination rates—such as safety concerns [43], scheduling conflicts with antineoplastic treatment [44], lack of awareness [45], or vaccine hesitancy [46, 47]—is also crucial. Improving education, refining vaccination protocols, and monitoring immune responses could help increase vaccination rates and better protect these patients [48].

Our study cohort was characterized by a high prevalence of lymphomas, particularly non-Hodgkin lymphoma, followed by plasma cell malignancies and acute myeloid leukemia. This distribution matches patterns seen previously in CARV [2, 23]. Interestingly, we found no significant differences in 30-day mortality based on malignancy treatment type, contrasting with some previous reports [6, 32, 49, 50]. Most of our patients had received drug-based chemotherapy in the past 3 months, indicating uniformly high immunosuppression. Although recent allogeneic HSCT is linked to higher CARV mortality in the literature [6, 32, 49–51], our study's broader timeframe (6 months) may account for this discrepancy, which also exists

in the literature, with reports describing the lack of correlation between HSCT and increased CARV-related mortality [52, 53]. Despite this, the high rate of active HM causing severe immune dysregulation, so as recent treatments likely contributed to increased vulnerability to viral infections, aligning with existing literature [54].

In addition to HM, a large number of patients had other underlying conditions that increased their risk of severe CARV infections. Chronic heart disease was the most common, followed by chronic lung disease, diabetes, and a history of smoking. These conditions weaken the immune system and complicate CARV infection management. Chronic heart disease was notably prevalent across all viral infections studied. Multiple comorbidities complicate treatment, possibly requiring specific antiviral medications or changes to malignancy treatment regimens. This highlights the need for a multidisciplinary approach involving not only infectious diseases and hematology but also cardiology, pulmonology, or endocrinology. Lymphopenia and prior corticosteroid use are also known to worsen outcomes in patients with CARV and HM [6, 7, 55]. Our study found that severe lymphopenia significantly increased mortality, but we did not collect data on corticosteroid use, limiting our analysis. Notably, smoking history emerged as a significant risk factor for mortality, a finding not widely reported. While smoking has been linked to severe RSV infections in HSCT patients [56], this was not observed in our study. Additionally, we did not find a significant link between neutropenia and mortality, despite prior research suggesting it correlates with RSV progression to lower respiratory tract infections [56].

Most patients had asymptomatic or mild infections, yet nearly 10% of the total required ICU admission, and half of those needed mechanical ventilation. Infection severity varied by pathogen, with influenza, parainfluenza, and metapneumovirus associated with higher rates of severe infection and ICU stays, in line with previous research [52, 53, 55, 57–59]. This variation could stem from virus pathogenicity, the level of patient immunosuppression, or existing underlying comorbidities. Notably, 39% of patients did not receive antiviral treatment, likely due to the mild nature of the infections, the lack of effective treatments [2], or concerns about drug interactions and toxicity [2]. Antiviral therapy, often combined with corticosteroids, was common for influenza and SARS-CoV-2, where effective options exist [25], improving management, outcomes, and burden to the health-care system. The lack of treatment options for viruses like metapneumovirus, parainfluenza, or RSV highlight the urgent need for improved antiviral prophylaxis and therapies for CARV infections, particularly in HM patients.

Secondary infections occurred in one in five patients, with bacterial infections being the most common, especially in those with rhinovirus and RSV infections. Bacterial coinfections complicate viral infections in HM patients, increasing morbidity and mortality [54, 55, 60–63]. The high rate of bacterial infections indicates that viral infections often impair mucosal barriers and immune responses, leading to bacterial overgrowth. In our study, bacterial secondary infections were linked to a four-fold increase in mortality risk, consistent with another research [54, 55, 64]. While less common, the risk of secondary fungal and viral infections highlights the severe immune suppression

in this group, particularly after recent treatments like chemotherapy, HSCT, or CAR-T therapy. Managing these infections requires a careful balance of timely antimicrobial treatment and resistance prevention.

The overall 30-day mortality rate was 6%, with significant variation among viruses. Both, the overall and attributable mortality rates were highest for parainfluenza, followed by influenza and metapneumovirus. The high mortality with parainfluenza, despite its lower prevalence, highlights the need for better antiviral options and the high vulnerability of HM patients. Key mortality risk factors included parainfluenza infection, smoking history, secondary bacterial infections, and hospital admission, particularly to the ICU, all of which have been widely reported in the literature [2, 3, 6, 7, 32, 54–56, 65, 66]. Conversely, the absence of lymphopenia was linked to lower mortality, suggesting that maintaining lymphocyte counts may be protective. Progression of the underlying malignancy was responsible for about 65% of deaths, but our focus was on overall mortality, as attributable mortality can be influenced by subjective clinical judgment.

Our registry study has several notable limitations. First, the study design did not allow us to calculate the incidence of CARV by HM type, as we lacked the necessary denominator, hindering our understanding of type-specific CARV rates. Second, there may be an underestimation of CARV cases due to a likely bias toward documenting more severe infections, which could lead to overestimating their severity. Third, with only about 5% of patients vaccinated, our study was limited in assessing vaccine effectiveness for preventing severe disease or modifying infection outcomes. This finding underscores the urgent need to enhance vaccination efforts among HM patients and their close contacts—including family members and healthcare workers—especially given the seasonal peaks of these respiratory infections. The cyclical pattern and respiratory transmission of CARVs like SARS-CoV-2 and influenza indicate that coordinating vaccinations with peak viral circulation periods could offer greater protection. The low vaccination rate reported in our cohort may partly result from underreporting in medical records but also highlights a preventive gap that could leave many patients vulnerable. Expanding vaccine coverage and providing timely boosters when available could strengthen immunity during high-risk periods, reducing the impact of severe CARV infections in this high-risk group. Fourth, the observational nature of the study introduces potential selection and reporting biases. Additionally, differences in healthcare access and prescription practices across the participating countries complicate the analysis of CARV treatments, particularly given the lack of standardized protocols for managing these infections. Furthermore, the study did not include detailed data on specific viral strains or variants, which could influence the outcomes, especially for SARS-CoV-2 and influenza.

In conclusion, our research shows how CARV pose a significant risk to HM patients, with elevated mortality linked to active malignancies, secondary bacterial infections, ICU admissions, and lymphopenia. The study observed seasonal peaks, with SARS-CoV-2 dominating late 2023 and influenza in early 2024, emphasizing the need for seasonally adjusted preventive strategies. Low vaccination rates among HM

patients are concerning, highlighting the need for improved vaccine strategies. High comorbidity prevalence, particularly chronic heart and lung diseases, necessitates a multidisciplinary care approach. Severe CARV cases often required ICU care, underscoring the urgent need for better antiviral treatments, particularly for parainfluenza and metapneumovirus, while secondary bacterial infections significantly increased mortality risk.

### Author Contributions

J.S.-G., F.M., L.P., and O.A.C. contributed to the study design and study supervision. J.S.G. did the statistical plan and analysis. J.S.-G., F.M., and L.P. interpreted the data and wrote the article. All the authors recruited, and documented participants, critically read, reviewed, and agreed to publish the article. All authors had full access to the data and had final responsibility for the decision to submit for publication.

### Affiliations

<sup>1</sup>Faculty of Medicine, University of Cologne and University Hospital Cologne, Institute of Translational Research, Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany | <sup>2</sup>Faculty of Medicine, University of Cologne, University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany | <sup>3</sup>German Centre for Infection Research (DZIF), partner Site Bonn-Cologne, Cologne, Germany | <sup>4</sup>Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy | <sup>5</sup>Department of Haematology, University Hospital Ostrava, Ostrava, Czech Republic | <sup>6</sup>Department of Haematology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic | <sup>7</sup>Department of Hematology, South Division of Internal Medicine Clinic, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary | <sup>8</sup>Hematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy | <sup>9</sup>Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli – IRCCS, Rome, Italy | <sup>10</sup>Department of Internal Medicine, ADRZ, Goes, Netherlands | <sup>11</sup>Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy | <sup>12</sup>Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy | <sup>13</sup>UO Clinica Malattie Infettive, IRCCS Ospedale Policlinico San Martino, Genoa, Italy | <sup>14</sup>AOU Policlinico Rodolico San Marco, Catania, Italy | <sup>15</sup>Microbiology and Parasitology Department, University Hospital La Paz, Madrid, Spain | <sup>16</sup>CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain | <sup>17</sup>Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy | <sup>18</sup>Department of Hematology and Oncology, Hospital Morales Messeguer, Murcia, Spain | <sup>19</sup>Department of Hematology, Blood Neoplasms, and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland | <sup>20</sup>Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck (MUI), Innsbruck, Austria | <sup>21</sup>University Hospital Hradec Králové, Hradec Králové, Czech Republic | <sup>22</sup>Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic | <sup>23</sup>Laikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece | <sup>24</sup>Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey | <sup>25</sup>Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium | <sup>26</sup>Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain | <sup>27</sup>Department of Hematology, Research Unit, Hospital Universitario de Burgos, Burgos, Spain | <sup>28</sup>Medizinische Klinik II, Klinikum Rechts der Isar, TU München, Munich, Germany | <sup>29</sup>Comenius University and National

Cancer Institute, Bratislava, Slovakia | <sup>30</sup>Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy | <sup>31</sup>Hematology Unit, Center for Translational Medicine, AziendaUSL Toscana NordOvest, Livorno, Italy | <sup>32</sup>National Cancer Institute, Fondazione ‘G. Pascale’, IRCCS, Hematology-Oncology and Stem Cell Transplantation Unit, Naples, Italy | <sup>33</sup>Hospital Nuestra Señora de Sonsoles, Ávila, Spain | <sup>34</sup>IRCCS Ospedale San Raffaele, Milan, Italy | <sup>35</sup>Hematology Unit, ASST-Spedali Civili, Brescia, Italy | <sup>36</sup>Division of Hematology, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary | <sup>37</sup>Department of Hematology, University Hospital Virgen Macarena – University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), Universidad de Sevilla (Departamento de Medicina), Seville, Spain | <sup>38</sup>Ematologia Con Trapianto, Ospedale Dimiccoli Barletta, Barletta, Italy | <sup>39</sup>McGill University Health Centre, Montreal, Canada | <sup>40</sup>Gomel State Medical University, Gomel, Belarus | <sup>41</sup>University Hospital Olomouc, Olomouc, Czech Republic | <sup>42</sup>Hematology and Bone Marrow Unit, Hospital University of Parma, Parma, Italy | <sup>43</sup>Azienda Ospedaliera Sant’Anna e San Sebastiano, Caserta, Italy | <sup>44</sup>Head ICU and CRC, Centre Hospitalier Victor DUPOUY, Argenteuil, France | <sup>45</sup>Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt | <sup>46</sup>Department of Pediatric Oncology, Children’s Cancer Hospital, Cairo, Egypt | <sup>47</sup>University Hospital Centre Zagreb, Zagreb, Croatia | <sup>48</sup>Croatian Cooperative Group for Hematological Diseases (CROHEM), Zagreb, Croatia | <sup>49</sup>Faculty of Medicine, University of Zagreb, Zagreb, Croatia | <sup>50</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy | <sup>51</sup>Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Istanbul University, Istanbul, Turkey | <sup>52</sup>North-Western State Medical University Named After Iliá Ilich Méchnikov, Saint-Petersburg, Russia | <sup>53</sup>University Clinical Center of Serbia, Belgrade, Serbia | <sup>54</sup>Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura Dei Tumori (IRST) IRCCS, Meldola, Italy | <sup>55</sup>Servicio de Hematología y Hemoterapia, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain | <sup>56</sup>Medical University of Warsaw, Warszawa, Poland | <sup>57</sup>University Medical Center Groningen, Groningen, The Netherlands | <sup>58</sup>Department of Clinical Microbiology, Maria Skłodowska-Curie National Research Institute of Oncology, Warszawa, Poland | <sup>59</sup>Ospedale Vito Fazzi, Lecce, Italy | <sup>60</sup>University Clinic of Hematology, Skopje, North Macedonia | <sup>61</sup>Faculty of Medicine, Mansoura University, Mansoura, Egypt | <sup>62</sup>King Faisal Specialist Hospital, Jeddah, Saudi Arabia | <sup>63</sup>Hematology and Transplant Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy | <sup>64</sup>University of Kansas Medical Center, Kansas City, Missouri, USA | <sup>65</sup>Department of Infectious Diseases, Hospital Clinic de Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain | <sup>66</sup>Northumbria Healthcare, Newcastle, UK | <sup>67</sup>Hospital Rey Juan Carlos, Móstoles, Spain | <sup>68</sup>General Hospital of Thessaloniki “George Papanikolaou”, Thessaloniki, Greece | <sup>69</sup>Department of Mental Health and Public Medicine, University of Campania, Naples, Italy | <sup>70</sup>Stem Cell Transplant Center, AOU Città della Salute e della Scienza, Turin, Italy | <sup>71</sup>Department of Oncology, Hematology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany | <sup>72</sup>Department of Hematology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark | <sup>73</sup>University Medical Center Hamburg-Eppendorf, Hamburg, Germany | <sup>74</sup>CRA From CRC Centre Hospitalier Victor DUPOUY, Argenteuil, France | <sup>75</sup>Maria Skłodowska-Curie Institute of Oncology, Warszawa, Poland | <sup>76</sup>Faculty of Medicine, University of Cologne and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany | <sup>77</sup>Hematology Unit, Università Cattolica del Sacro Cuore, Rome, Italy

## Acknowledgments

We would like to express our deepest gratitude to everyone who contributed to the development of this manuscript. In particular, we wish to pay special tribute to Dr. Alberto López-García. His dedication, knowledge, and unwavering support have been instrumental in advancing the EPICOVIDEHA-EPIFLUEHA research since its inception. His legacy

will endure through this work, and he will always be remembered with great appreciation and respect.

## Conflicts of Interest

The authors declare no conflicts of interest.

## Data Availability Statement

The corresponding author can provide the data supporting the findings of this study upon a reasonable request.

## References

1. R. Martino, E. Ramila, N. Rabella, et al., “Respiratory Virus Infections in Adults With Hematologic Malignancies: A Prospective Study,” *Clinical Infectious Diseases* 36, no. 1 (2003): 1–8.
2. G. Gabutti, F. De Motoli, F. Sandri, M. V. Toffoletto, and A. Stefanati, “Viral Respiratory Infections in Hematological Patients,” *Infectious Diseases and Therapy* 9, no. 3 (2020): 495–510.
3. L. Fontana and L. Strasfeld, “Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient,” *Infectious Disease Clinics of North America* 33, no. 2 (2019): 523–544.
4. C. M. Popescu, A. L. Ursache, G. Feketea, et al., “Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients?,” *Microorganisms* 7, no. 11 (2019): 521.
5. M. von Lilienfeld-Toal, A. Berger, M. Christopheit, et al., “Community Acquired Respiratory Virus Infections in Cancer Patients-Guideline on Diagnosis and Management by the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology,” *European Journal of Cancer* 67 (2016): 200–212.
6. H. H. Hirsch, R. Martino, K. N. Ward, M. Boeckh, H. Einsele, and P. Ljungman, “Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus,” *Clinical Infectious Diseases* 56, no. 2 (2013): 258–266.
7. D. Engelhard, B. Mohty, R. de la Camara, C. Cordonnier, and P. Ljungman, “European Guidelines for Prevention and Management of Influenza in Hematopoietic Stem Cell Transplantation and Leukemia Patients: Summary of ECIL-4 (2011), on Behalf of ECIL, a Joint Venture of EBMT, EORTC, ICHS, and ELN,” *Transplant Infectious Disease* 15, no. 3 (2013): 219–232.
8. J. Salmanton-Garcia, A. Busca, O. A. Cornely, et al., “EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19,” *Hema* 5, no. 7 (2021): e612.
9. T. F. Aiello, J. Salmanton-Garcia, F. Marchesi, et al., “Dexamethasone Treatment for COVID-19 Is Related to Increased Mortality in Hematologic Malignancy Patients: Results From the EPICOVIDEHA Registry,” *Haematologica* 109, no. 8 (2024): 2693–2700.
10. O. Blennow, J. Salmanton-Garcia, P. Nowak, et al., “Outcome of Infection With Omicron SARS-CoV-2 Variant in Patients With Hematological Malignancies: An EPICOVIDEHA Survey Report,” *American Journal of Hematology* 97, no. 8 (2022): E312–E317.
11. A. Busca, J. Salmanton-Garcia, F. Marchesi, et al., “Outcome of COVID-19 in Allogeneic Stem Cell Transplant Recipients: Results From the EPICOVIDEHA Registry,” *Frontiers in Immunology* 14 (2023): 1125030.
12. C. Cattaneo, J. Salmanton-Garcia, F. Marchesi, et al., “Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey,” *Cancers (Basel)* 14, no. 22 (2022): 5530.
13. M. Criscuolo, J. Salmanton-Garcia, N. Fracchiolla, et al., “SARS-CoV-2 Infection in Patients With Mastocytosis: An EPICOVIDEHA

- Report,” *Journal of Investigational Allergology & Clinical Immunology* 33, no. 3 (2023): 225–227.
14. S. El-Ashwah, J. Salmanton-Garcia, Y. M. Bilgin, et al., “The Mortality of COVID-19 in CML Patients From 2020 Until 2022: Results From the EPICOVIDEHA Survey,” *Leukemia & Lymphoma* 65, no. 2 (2024): 199–208.
15. M. S. Infante, J. Salmanton-Garcia, A. Fernandez-Cruz, et al., “B-Cell Malignancies Treated With Targeted Drugs and SARS-CoV-2 Infection: A European Hematology Association Survey (EPICOVIDEHA),” *Frontiers in Oncology* 12 (2022): 992137.
16. T. Lahmer, J. Salmanton-Garcia, F. Marchesi, et al., “Need for ICU and Outcome of Critically Ill Patients With COVID-19 and Haematological Malignancies: Results From the EPICOVIDEHA Survey,” *Infection* 52, no. 3 (2024): 1125–1141.
17. S. Lamure, J. Salmanton-Garcia, E. Robin-Marieton, et al., “COVID-19 and Hairy-Cell Leukemia: An EPICOVIDEHA Survey,” *Blood Advances* 6, no. 13 (2022): 3870–3874.
18. F. Marchesi, J. Salmanton-Garcia, C. Buquicchio, et al., “Passive Pre-Exposure Immunization by Tixagevimab/Cilgavimab in Patients With Hematological Malignancy and COVID-19: Matched-Paired Analysis in the EPICOVIDEHA Registry,” *Journal of Hematology & Oncology* 16, no. 1 (2023): 32.
19. F. Marchesi, J. Salmanton-Garcia, Z. Emarah, et al., “COVID-19 in Adult Acute Myeloid Leukemia Patients: A Long-Term Follow-Up Study From the European Hematology Association Survey (EPICOVIDEHA),” *Haematologica* 108, no. 1 (2023): 22–33.
20. M. Marchetti, J. Salmanton-Garcia, S. El-Ashwah, et al., “Outcomes of SARS-CoV-2 Infection in Ph-Neg Chronic Myeloproliferative Neoplasms: Results From the EPICOVIDEHA Registry,” *Therapeutic Advances in Hematology* 14 (2023): 20406207231154706.
21. P. Musto, J. Salmanton-Garcia, N. Sgherza, et al., “Survival in Multiple Myeloma and SARS-COV-2 Infection Through the COVID-19 Pandemic: Results From the EPICOVIDEHA Registry,” *Hematological Oncology* 42, no. 1 (2024): e3240.
22. L. Pagano, J. Salmanton-Garcia, F. Marchesi, et al., “Breakthrough COVID-19 in Vaccinated Patients With Hematologic Malignancies: Results From the EPICOVIDEHA Survey,” *Blood* 140, no. 26 (2022): 2773–2787.
23. L. Pagano, J. Salmanton-Garcia, F. Marchesi, et al., “COVID-19 Infection in Adult Patients With Hematological Malignancies: A European Hematology Association Survey (EPICOVIDEHA),” *Journal of Hematology & Oncology* 14, no. 1 (2021): 168.
24. G. Rossi, J. Salmanton-Garcia, C. Cattaneo, et al., “Age, Successive Waves, Immunization, and Mortality in Elderly COVID-19 Hematological Patients: EPICOVIDEHA Findings,” *International Journal of Infectious Diseases* 137 (2023): 98–110.
25. J. Salmanton-Garcia, F. Marchesi, F. Farina, et al., “Decoding the Historical Tale: COVID-19 Impact on Haematological Malignancy Patients-EPICOVIDEHA Insights From 2020 to 2022,” *EclinicalMedicine* 71 (2024): 102553.
26. J. Salmanton-Garcia, F. Marchesi, A. Glenthøj, et al., “Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report,” *Hema* 6, no. 11 (2022): e789.
27. J. Salmanton-Garcia, F. Marchesi, M. Gomes da Silva, et al., “Nirmatrelvir/Ritonavir in COVID-19 Patients With Haematological Malignancies: A Report From the EPICOVIDEHA Registry,” *EclinicalMedicine* 58 (2023): 101939.
28. J. Salmanton-Garcia, F. Marchesi, P. Koehler, et al., “Molnupiravir Compared to Nirmatrelvir/Ritonavir for COVID-19 in High-Risk Patients With Haematological Malignancy in Europe. A Matched-Paired Analysis From the EPICOVIDEHA Registry,” *International Journal of Antimicrobial Agents* 62, no. 4 (2023): 106952.
29. J. A. van Doesum, J. Salmanton-Garcia, F. Marchesi, et al., “Impact of SARS-CoV-2 Vaccination and Monoclonal Antibodies on Outcome Post-CD19-Directed CAR T-Cell Therapy: An EPICOVIDEHA Survey,” *Blood Advances* 7, no. 11 (2023): 2645–2655.
30. J. Salmanton-Garcia, F. Marchesi, F. Itri, et al., “Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients,” *Hema* 7, no. 11 (2023): e970.
31. L. Garcia-Arroyo, N. Prim, M. Del Cuerpo, et al., “Prevalence and Seasonality of Viral Respiratory Infections in a Temperate Climate Region: A 24-Year Study (1997-2020),” *Influenza and Other Respiratory Viruses* 16, no. 4 (2022): 756–766.
32. E. Atalla, M. Kalligeros, E. K. Mylona, et al., “Impact of Influenza Infection Among Adult and Pediatric Populations With Hematologic Malignancy and Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis,” *Clinical Therapeutics* 43, no. 5 (2021): e66–e85.
33. Y. Kaku, K. Okumura, M. Padilla-Blanco, et al., “Virological Characteristics of the SARS-CoV-2 JN.1 Variant,” *Lancet Infectious Diseases* 24, no. 2 (2024): e82.
34. Y. Goldberg and A. Huppert, “To Boost or Not to Boost: Navigating Post-Pandemic COVID-19 Vaccination,” *Lancet Respiratory Medicine* 11, no. 12 (2023): 1039–1041.
35. J. V. Lazarus, T. M. White, K. Wyka, et al., “Influence of COVID-19 on Trust in Routine Immunization, Health Information Sources and Pandemic Preparedness in 23 Countries in 2023,” *Nature Medicine* 30, no. 6 (2024): 1559–1563.
36. C. Liu, J. Huang, S. Chen, et al., “The Impact of Crowd Gatherings on the Spread of COVID-19,” *Environmental Research* 213 (2022): 113604.
37. L. Gur-Arie, M. Stein, H. Sefty, et al., “Hospital Surveillance of Respiratory Viruses During the COVID-19 Pandemic and Beyond: Contribution to the WHO Mosaic Framework, Israel, 2020 to 2023,” *Euro Surveillance* 29, no. 32 (2024): 2300634.
38. R. F. Chemaly, D. P. Shah, and M. J. Boeckh, “Management of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies,” *Clinical Infectious Diseases* 59, no. Suppl 5 (2014): S344–S351.
39. S. S. Lee, C. Viboud, and E. Petersen, “Understanding the Rebound of Influenza in the Post COVID-19 Pandemic Period Holds Important Clues for Epidemiology and Control,” *International Journal of Infectious Diseases* 122 (2022): 1002–1004.
40. C. G. Pendrey, J. Strachan, H. Peck, et al., “The re-Emergence of Influenza Following the COVID-19 Pandemic in Victoria, Australia, 2021 to 2022,” *Euro Surveillance* 28, no. 37 (2023): 2300118.
41. CDC: Centers for Disease Control and Prevention, “Immunization Recommendations for the 2023–2024 Respiratory Disease Season: At-A-Glance11/24/2023 CS-343797A INFLUENZA • COVID-19 • RSV,” (2023), <https://www.cdc.gov/respiratory-viruses/tools-resources/downloads/respiratory-disease-at-a-glance-508.pdf>.
42. A. Das Barshan and E. L. A. Matsumoto-Takahashi, “Efficacy of COVID-19 Vaccines in Patients With Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-Analysis,” *Japan Medical Association Journal* 7, no. 2 (2024): 153–171.
43. C. C. Lai, I. T. Chen, C. M. Chao, P. I. Lee, W. C. Ko, and P. R. Hsueh, “COVID-19 Vaccines: Concerns Beyond Protective Efficacy and Safety,” *Expert Review of Vaccines* 20, no. 8 (2021): 1013–1025.
44. S. Cesaro, M. Mikulska, H. H. Hirsch, et al., “Update of Recommendations for the Management of COVID-19 in Patients With Haematological Malignancies, Haematopoietic Cell Transplantation and CAR T

- Therapy, From the 2022 European Conference on Infections in Leukemia (ECIL 9)," *Leukemia* 37, no. 9 (2023): 1933–1938.
45. E. M. La, S. Bunniran, D. Garbinsky, et al., "Respiratory Syncytial Virus Knowledge, Attitudes, and Perceptions Among Adults in the United States," *Human Vaccines and Immunotherapeutics* 20, no. 1 (2024): 2303796.
46. S. Schumacher, J. Salmanton-Garcia, A. Liekweg, et al., "Increasing Influenza Vaccination Coverage in Healthcare Workers: Analysis of an Intensified on-Site Vaccination Campaign During the COVID-19 Pandemic," *Infection* 51, no. 5 (2023): 1417–1429.
47. S. Schumacher, J. Salmanton-Garcia, O. A. Cornely, and S. C. Mellinghoff, "Increasing Influenza Vaccination Coverage in Healthcare Workers: A Review on Campaign Strategies and Their Effect," *Infection* 49, no. 3 (2021): 387–399.
48. L. M. Cremer, B. Bethe, P. Borchmann, et al., "Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for a Multicenter Prospective Non-Interventional Study," *JMIR Research Protocols* (2024).
49. C. M. Mulrone, M. B. Abid, A. Bashey, et al., "Incidence and Impact of Community Respiratory Viral Infections in Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis and Haploidentical Stem Cell Transplantation," *British Journal of Haematology* 194, no. 1 (2021): 145–157.
50. E. Vakil and S. E. Evans, "Viral Pneumonia in Patients With Hematologic Malignancy or Hematopoietic Stem Cell Transplantation," *Clinical Chest Medicine* 38, no. 1 (2017): 97–111.
51. J. N. Shah and R. F. Chemaly, "Management of RSV Infections in Adult Recipients of Hematopoietic Stem Cell Transplantation," *Blood* 117, no. 10 (2011): 2755–2763.
52. D. P. Shah, P. K. Shah, J. M. Azzi, F. El Chaer, and R. F. Chemaly, "Human Metapneumovirus Infections in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients: A Systematic Review," *Cancer Letters* 379, no. 1 (2016): 100–106.
53. D. P. Shah, P. K. Shah, J. M. Azzi, and R. F. Chemaly, "Parainfluenza Virus Infections in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients: A Systematic Review," *Cancer Letters* 370, no. 2 (2016): 358–364.
54. S. Unal, P. Schnitzler, N. Giesen, M. Wedde, R. Durrwald, and J. Tabatabai, "Molecular Epidemiology and Disease Severity of Influenza Virus Infection in Patients With Haematological Disorders," *Journal of Medical Virology* 95, no. 6 (2023): e28835.
55. J. Tabatabai, P. Schnitzler, C. Prifert, et al., "Parainfluenza Virus Infections in Patients With Hematological Malignancies or Stem Cell Transplantation: Analysis of Clinical Characteristics, Nosocomial Transmission and Viral Shedding," *PLoS One* 17, no. 7 (2022): e0271756.
56. F. Khawaja and R. F. Chemaly, "Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies," *Haematologica* 104, no. 7 (2019): 1322–1331.
57. C. Lefevre, M. Salmons, L. Bondeelle, et al., "Frequent Lower Respiratory Tract Disease in Hematological Patients With Parainfluenza Virus Type 3 Infection," *Journal of Medical Virology* 93, no. 11 (2021): 6371–6376.
58. C. Pochon and S. Voigt, "Respiratory Virus Infections in Hematopoietic Cell Transplant Recipients," *Frontiers in Microbiology* 9 (2018): 3294.
59. H. Hakim, R. Dallas, Y. Zhou, et al., "Acute Respiratory Infections in Children and Adolescents With Acute Lymphoblastic Leukemia," *Cancer* 122, no. 5 (2016): 798–805.
60. L. Vanderbeke, I. Spriet, C. Breynaert, B. J. A. Rijnders, P. E. Verweij, and J. Wauters, "Invasive Pulmonary Aspergillosis Complicating Severe Influenza: Epidemiology, Diagnosis and Treatment," *Current Opinion in Infectious Diseases* 31, no. 6 (2018): 471–480.
61. E. Goka, P. Valley, K. Mutton, and P. Klapper, "Influenza A Viruses Dual and Multiple Infections With Other Respiratory Viruses and Risk of Hospitalisation and Mortality," *Influenza and Other Respiratory Viruses* 7, no. 6 (2013): 1079–1087.
62. C. Garcia-Vidal, P. Barba, M. Arnan, et al., "Invasive Aspergillosis Complicating Pandemic Influenza A (H1N1) Infection in Severely Immunocompromised Patients," *Clinical Infectious Diseases* 53, no. 6 (2011): e16–e19.
63. A. Schauwvlieghe, B. J. A. Rijnders, N. Philips, et al., "Invasive Aspergillosis in Patients Admitted to the Intensive Care Unit With Severe Influenza: A Retrospective Cohort Study," *Lancet Respiratory Medicine* 6, no. 10 (2018): 782–792.
64. T. Rachow, T. Lamik, J. Kalkreuth, et al., "Detection of Community-Acquired Respiratory Viruses in Allogeneic Stem-Cell Transplant Recipients and Controls—A Prospective Cohort Study," *Transplant Infectious Disease* 22, no. 6 (2020): e13415.
65. K. Sanli, M. Ayer, S. Alacam, A. Gumus, and N. Karabulut, "Retrospective Analysis of Respiratory Virus Infections in Adults With Hematologic Malignancies," *European Review for Medical and Pharmaceutical Sciences* 27, no. 21 (2023): 10785–10797.
66. S. Abbas, J. E. Raybould, S. Sastry, and O. de la Cruz, "Respiratory Viruses in Transplant Recipients: More Than Just a Cold. Clinical Syndromes and Infection Prevention Principles," *International Journal of Infectious Diseases* 62 (2017): 86–93.

### Supporting Information

Additional supporting information can be found online in the Supporting Information section.